Final Results of Phase 2 Clinical Trial Program Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Decrease Risk of Hospitalization and All-Cause Mortality in Heart Failure Patients with Anemia, Based on a Prespecified Pooled Analysis
Results Validate Amgen's Phase 3 RED-HF(TM)
Trial to Address Unmet Medical Need
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--June 19, 2006--
Amgen (Nasdaq:AMGN), the world's largest biotechnology company,
announced results at the 2006 European Society of Cardiology-Heart
Failure (ESC-HF) Congress from a Phase 2 study showing that, in
patients with symptomatic heart failure and anemia, Aranesp(R)
(darbepoetin alfa) was well tolerated and effectively raised
hemoglobin (Hb) (Abstract # 60734). Amgen also announced results from
a prespecified pooled analysis including these data and data from a
second Phase 2 study presented in March 2006 at the American College
of Cardiology (ACC) Scientific Session showing that treatment with
Aranesp may decrease the risk of heart failure hospitalization and
all-cause mortality, and improve symptoms (Abstract #60731). These
results require confirmation from a large Phase 3 randomized
controlled clinical trial.
"These results are especially encouraging because, currently,
there are no approved treatments to address the debilitating effects
of anemia associated with symptomatic heart failure," said Dirk J. van
Veldhuisen, M.D., Department of Cardiology/Thoracic Surgery,
University Medical Center, Groningen, Netherlands. "The final results
of the Phase 2 program validate the importance of Amgen's recently
launched large-scale Phase 3 RED-HF(TM) Trial or Reduction of Events
with Darbepoetin alfa in Heart Failure Trial, which will evaluate the
effect of treatment of anemia with Aranesp on morbidity and mortality
in patients with symptomatic heart failure."
Heart failure affects more than 23 million people worldwide and
over five million people in the U.S. Heart failure alone is the
leading cause of hospitalization for people over the age of 65 years
and causes almost one million hospitalizations every year.
Approximately 20 to 30 percent of people diagnosed with heart
failure also suffer from anemia, resulting in increased risk of
morbidity and mortality versus patients who suffer from heart failure
without anemia. Even though there are current, approved therapies to
treat heart failure, a significant unmet medical need to treat the
disease and its complications still exists.
"Despite medical advances, heart failure and its complications are
a leading cause of death and hospitalization worldwide," said Willard
Dere, M.D., senior vice president for Global Development and chief
medical officer at Amgen. "Amgen is committed to investigating the
potential that Aranesp may provide heart failure patients, who also
suffer from anemia, a new treatment option through the RED-HF(TM)
About the Phase 2 Data Presented at ESC
This one-year study enrolled 319 patients with symptomatic heart
failure (NYHA II-IV), left ventricular ejection fraction (LVEF) of
less than or equal to 40 percent and Hb levels of 9.0 to 12.5 g/dL who
were randomized to receive placebo (n=157) or Aranesp (n=162).
Endpoints were change in exercise time (ET); NYHA class; Minnesota
Living with Heart Failure Questionnaire (MLHFQ) score at 6 months;
heart failure hospitalization and mortality at one year and safety.
Results showed that baseline characteristics of treatment groups
were similar. In patients with symptomatic heart failure and anemia,
treatment with Aranesp effectively raised Hb (mean (SE) 1.80 (0.10)
Aranesp versus 0.45 (0.10) placebo) and showed trends suggestive of a
benefit in exercise duration (adjusted mean 57.3 seconds Aranesp
versus 46.5 seconds placebo) and clinical outcomes (NYHA adjusted mean
-0.19 Aranesp versus -0.13 placebo; MLHFQ mean -9.3 Aranesp versus
-7.1 placebo). The hazard ratio (95 percent CI) for first HF
hospitalization or mortality was 0.68 (0.43, 1.08; p=0.10).
The study showed that the treatment with Aranesp was well
tolerated; eight percent of patients (n=13) experienced hypertension
versus six percent (n=10) in placebo, 23 percent of patients' heart
failure was exacerbated (n=38) versus 29 percent (n=45) in placebo,
two percent of patients (n=4) had a myocardial infarction versus three
percent (n=5) placebo and no patients (n=0) in the Aranesp arm
experienced deep vein thrombosis while one percent (n=2) did in the
About the Pooled Analysis Presented at ESC
The pooled analysis based on the two largest multicenter
randomized control trials (RCTs) evaluating the safety and efficacy of
Aranesp treatment in 475 patients with symptomatic heart failure and
anemia, LVEF less than or equal to 40 percent and Hb levels of 9.0 to
12.5 g/dL. Patients were randomized to placebo (n=209) or Aranesp
(n=266) subcutaneously every two weeks for up to one year. The
endpoints were change from baseline in NYHA class; Patient's Global
Assessment (PGA); MLHFQ scores at six months (individual studies); and
the composite of all-cause mortality or first HF-related
hospitalization, HF-related hospitalization, all-cause mortality and
safety at one year.
The pooled analyses suggested that treatment with Aranesp may
improve symptoms and may decrease the risk of the composite of
all-cause mortality or first heart failure-related hospitalization
(hazard ratio 0.67 (0.44, 1.03) p= 0.064), of heart-failure related
hospitalization (hazard ratio 0.66 (0.40, 1.07) p= 0.091) and of
all-cause mortality (hazard ratio 0.76 (0.39, 1.48) p= 0.418).
Adverse events were similar in both treatment groups (Aranesp
versus placebo): hypertension (6 percent n=15 versus 6 percent n=12),
deep vein thrombosis (zero percent n=0 versus one percent n=2),
worsening heart failure (19 percent n=50 versus 25 percent n=53) and
myocardial infarction (two percent n=6 versus two percent n=5).
About Aranesp(R) (darbepoetin alfa)
Aranesp is a recombinant erythropoietic protein (a protein that
stimulates production of red blood cells, which carry oxygen). Amgen
revolutionized the treatment of anemia with the development of
recombinant erythropoietin, Epoetin alfa. Building on this heritage,
Amgen developed Aranesp, a unique erythropoiesis stimulating protein,
which contains two additional sialic acid-containing carbohydrate
chains compared to the Epoetin alfa molecule and remains in the
bloodstream longer than Epoetin alfa because it has a longer
half-life. Aranesp was approved by the U.S. Food and Drug
Administration (FDA) in September 2001 for the treatment of anemia
associated with chronic renal failure, also known as chronic kidney
disease (CKD), for patients on dialysis and patients not on dialysis.
In July 2002, Aranesp was approved by the FDA for the treatment of
chemotherapy-induced anemia in patients with non-myeloid malignancies.
Aranesp was granted marketing authorization by the European
Commission in 2001 for the treatment of anemia associated with chronic
renal failure in adults and pediatric subjects 11 years of age or
older. Approval was granted in 2004 for an extended dosing of up to
once monthly for the treatment of anemia in CKD patients not on
dialysis. In 2006 the Aranesp label was updated to allow CKD patients
on dialysis to switch from EPO two to three times a week to Aranesp
every two weeks.
Important Safety Information
Aranesp is contraindicated in patients with uncontrolled
hypertension. Erythropoietic therapies may increase the risk of
thrombotic events and other serious events. The target hemoglobin (Hb)
should not exceed 12 g/dL. If the Hb increase exceeds 1.0 g/dL in any
2-week period, dose reductions are recommended. In a study with
another erythropoietic product, where the target Hb was 12 - 14 g/dL,
an increased incidence of thrombotic events, disease progression, and
mortality was seen.
Cases of pure red cell aplasia (PRCA) and of severe anemia, with
or without other cytopenias associated with neutralizing antibodies to
erythropoietin have been reported in patients treated with Aranesp.
This has been reported predominately in patients with chronic renal
failure (CRF) receiving Aranesp by subcutaneous administration. A
sudden loss of response to Aranesp, accompanied by severe anemia and
low reticulocyte count, should be evaluated. If anti-erythropoietin
antibody-associated anemia is suspected, withhold Aranesp and other
erythropoietic proteins. Aranesp should be permanently discontinued in
patients with antibody-mediated anemia. Patients should not be
switched to other erythropoietic proteins.
The most commonly reported side effects in clinical trials were
fatigue, edema, nausea, vomiting, diarrhea, fever and dyspnea.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in Amgen's Form 10-K for the year ended
December 31, 2005, and in Amgen's periodic reports on Form 10-Q and
Form 8-K. Amgen is providing this information as of the date of this
news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify side effects or manufacturing problems with
our products after they are on the market. In addition, sales of our
products are affected by the availability of reimbursement and the
reimbursement policies imposed by third party payors, including
governments, private insurance plans and managed care providers, and
may be affected by domestic and international trends toward managed
care and healthcare cost containment as well as possible U.S.
legislation affecting pharmaceutical pricing and reimbursement.
Government regulations and reimbursement policies may affect the
development, usage and pricing of our products. In addition, we
compete with other companies with respect to some of our marketed
products as well as for the discovery and development of new products.
We believe that some of our newer products, product candidates or new
indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against
products that have lower prices, established reimbursement, superior
performance, are easier to administer, or that are otherwise
competitive with our products. In addition, while we routinely obtain
patents for our products and technology, the protection offered by our
patents and patent applications may be challenged, invalidated or
circumvented by our competitors and there can be no guarantee of our
ability to obtain or maintain patent protection for our products or
product candidates. We cannot guarantee that it will be able to
produce commercially successful products or maintain the commercial
success of our existing products.
Our stock price may be affected by actual or perceived market
opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate
an entire class of products could have a material adverse effect on
sales of the affected products and on our business and results of
operations. The scientific information discussed in this news release
related to our product candidates is preliminary and investigative.
Such product candidates are not approved by the U.S. Food and Drug
Administration (FDA), and no conclusions can or should be drawn
regarding the safety or effectiveness of the product candidates. Only
the FDA can determine whether the product candidates are safe and
effective for the use(s) being investigated. Further, the scientific
information discussed in this news release relating to new indications
for our products is preliminary and investigative and is not part of
the labeling approved by the FDA for the products. The products are
not approved for the investigational use(s) discussed in this news
release, and no conclusions can or should be drawn regarding the
safety or effectiveness of the products for these uses. Only the FDA
can determine whether the products are safe and effective for these
uses. Healthcare professionals should refer to and rely upon the
FDA-approved labeling for the products, and not the information
discussed in this news release.
EDITOR'S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Marie Fay, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)